Clinical trials: Sexually Active
Cardiovascular Diseases, Diabetes Mellitus
Retrospective Evaluation of Athens Complete Health Improvement Program (CHIP) Database
Data from participants in Athens CHIP classes from May 2011 to present will be analyzed to evaluate the differences in outcomes based on: 1) gender, 2) age, 3) whether a household member participated in the class with them.
- Conditions
- Cardiovascular Diseases, Diabetes Mellitus, Hypertension, Dyslipidemias
- Trial name
- NCT03025451
- Testing
- The Complete Health Improvement Program
- Where
- United States
- Volunteers
- 512 people, healthy volunteers welcome
- Sponsor
- Ohio University
Sexual Function, Over Active Bladder
The Effect Of Pelvic Floor Muscle Exercises On Sexual Life In Women With Overactive Bladder
This is a randomized controlled experimental study to determine the effect of pelvic floor muscle exercise on sexual life. The study included 64 women admitted to the Erzurum City Hospital, who consented to participate.
- Trial name
- NCT07030608
- Testing
- Exercise
- Where
- Turkey (Türkiye)
- Volunteers
- 64 people
- Sponsor
- Biruni University
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)
Investigators are trying to find better treatments for people with HIV-1. In this clinical study, investigators want to see how well a new treatment called ISL+ULO, taken once a week, works compared to an existing treatment…
- Trial name
- NCT06891066
- Testing
- ISL, ULO, BIC/FTC/TAF
- Where
- 23 sites in United States, Australia and 2 more
- Volunteers
- 150 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs
The purpose of this study is to see if it is safe to give indinavir (IDV) and ritonavir (RTV) in combination with stavudine (d4T) and lamivudine (3TC) to HIV-positive patients who have never received anti-HIV therapy.
- Trial name
- NCT00002451
- Testing
- Indinavir sulfate, Ritonavir, Lamivudine
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Merck Sharp & Dohme LLC
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
Researchers are looking for new ways to treat HIV-1 (Human Immunodeficiency Virus Type 1). The usual (standard) treatment for HIV-1 is antiretroviral therapy (ART), which includes taking medicines to lower the amount of HIV-1 in…
- Trial name
- NCT07266831
- Testing
- ISL, ULO, BIC/FTC/TAF
- Where
- 55 sites in United States, Argentina and 7 more
- Volunteers
- 570 people
- Sponsor
- Merck Sharp & Dohme LLC
ANCA-IgG-positive ANCA Associated Vasculitis
Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis
The goal of this phase I/II clinical trial is to investigate anti-CD 19 chimeric antigen receptor T cell (CAR-T cell) therapy in patients with antineutrophil cytoplasmic antibodies (ANCA) immunoglobulin (IgG) positive ANCA…
- Trial name
- IDEAL (NCT06590545)
- Testing
- KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy
- Volunteers
- 8 people
- Sponsor
- David Simon
HIV Infections
Safety and Antiviral Activity of TPV in HCV and/or HBV HIV Coinfected Patients TDM Randomised Pilot Evaluation
The main purposes of this study are: demonstrate the safety and efficacy of TPV/r among HCV or hepatitis B virus (HBV) co-infected HIV+population, three-class (NRTI, NNRTI, and PI) experienced, with documented resistance to more…
- Trial name
- NCT00447902
- Testing
- tipranavir, ritonavir
- Where
- 30 sites in United States, Argentina and 5 more
- Volunteers
- 11 people
- Sponsor
- Boehringer Ingelheim
HIV Infections, Tuberculosis
A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin
To evaluate the methodology for rapidly determining the early bactericidal activity (EBA), tolerance, and pharmacokinetics of isoniazid and levofloxacin in the treatment of pulmonary tuberculosis (TB).
- Trial name
- NCT00000778
- Testing
- Isoniazid, Pyridoxine hydrochloride, Levofloxacin
- Where
- 10 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328
This study examines the long-term effects of interleukin-2 (IL-2) in combination with anti-HIV drugs, or highly active antiretroviral therapy (HAART).
- Trial name
- NCT00000923
- Testing
- Indinavir sulfate, Lamivudine, Stavudine
- Where
- 12 sites in United States
- Volunteers
- 110 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Anal Dysplasia, Human Papillomavirus
The HPV-SAVE Study Team: HPV Screening and Vaccine Evaluation in Men Who Have Sex With Men
Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide. Infection by certain high-risk oncogenic types of HPV (HR-HPV) is the major cause of several cancers in men, notably squamous cell carcinoma…
- Conditions
- Anal Dysplasia, Human Papillomavirus, Anal Cancer
- Trial name
- HPV-SAVE (NCT02503111)
- Testing
- The Hyfrecator ® 2000 Electrosurgical System, Observation Alone
- Where
- 4 sites in Canada
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Surgical Site Infection Prevention, Episiotomy Infection
Effect of Topical Diltiazem Plus Fusidic Acid Versus Fusidic Acid Alone on Episiotomy Healing, Pain, and Resumption of Sexual Activity: A Randomized Controlled Trial in Azadi Teaching Hospital
The goal of this clinical trial is to learn if diltiazem gel combined with fucidic acid cream works better than fucidic acid cream alone to prevent surgical site infection following episiotomy repair.
- Conditions
- Surgical Site Infection Prevention, Episiotomy Infection, Episiotomy Wound, Normal Vaginal Delivery
- Trial name
- NCT07545187
- Testing
- Group 1 received sequential topical diltiazem gel 2% followed by fusidic acid cream, and Group 2 received topical fusidic acid cream alone
- Where
- Iraq
- Volunteers
- 100 people
- Sponsor
- Alaa Nadhim Hameed
HIV Infection, Monoclonal Antibody, Human
Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), Administered Intravenously or Subcutaneously to Healthy Adults
Background: VRC01 is a manmade antibody directed against the human immunodeficiency virus (HIV). Antibodies fight infection. Researchers eventually want to know if VRC01 helps prevent or treat HIV infection.
- Conditions
- HIV Infection, Monoclonal Antibody, Human, HIV Antibodies, VRC01 Monoclonal Antibody
- Trial name
- NCT01993706
- Testing
- VRC-HIVMAB060-00-AB
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years
This is a 48-week study to collect additional information on the safety, tolerability, pharmacokinetics, and antiviral activity of an investigational regimen (course of therapy) including FDA approved HIV drugs in HIV-infected…
- Trial name
- NCT00040664
- Testing
- ritonavir, fosamprenavir
- Where
- 42 sites in United States, Canada and 5 more
- Volunteers
- 69 people
- Sponsor
- ViiV Healthcare
HIV Infection
A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002)
This Phase I study was directed at evaluating the safety profile and the immunogenicity of the vaccination with recombinant HIV-1 Tat and V2-deleted Env (delta-V2 Env) proteins administered in association in healthy…
- Trial name
- NCT01441193
- Testing
- HIV-1 Tat/delta-V2 Env combined vaccine, HIV-1 delta-V2 Env vaccine, HIV-1 Tat vaccine 7.5 microg
- Where
- 3 sites in Italy
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Barbara Ensoli, MD
HIV Infections
Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection
The purpose of this study is to evaluate the safety of the experimental drug Bay 50-4798 in HIV positive patients receiving HAART and to test the drug's effect on the CD4+ T-cell count.
- Trial name
- NCT00059462
- Testing
- Interleukin-2 SA, HAART
- Where
- 11 sites in United States, France and 1 more
- Volunteers
- 56 people
- Sponsor
- Bayer
HIV Infection
Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)
This study will evaluate the safety and efficacy of a switch to Doravirine/Islatravir (DOR/ISL) (MK-8591A) (a fixed dose combination of doravirine 100 mg and islatravir 0.75 mg) in participants living with human immunodeficiency…
- Trial name
- NCT04223791
- Testing
- DOR/ISL, BIC/FTC/TAF
- Where
- 89 sites in United States, Australia and 9 more
- Volunteers
- 643 people
- Sponsor
- Merck Sharp & Dohme LLC
Sexual Function Disturbances, Pelvic Organ Prolapse
Postoperative Return to Sexual Activity
To determine if standardized counselling regarding first sexual encounter after pelvic reconstructive surgery for pelvic organ prolapse and / or urinary incontinence improves postoperative preparedness to return to sexual…
- Conditions
- Sexual Function Disturbances, Pelvic Organ Prolapse, Stress Urinary Incontinence, Surgery
- Trial name
- PoRS (NCT05342090)
- Testing
- Structured Counselling Tool
- Where
- Canada
- Volunteers
- 186 people
- Sponsor
- University of Calgary
HIV Infections
A Randomized Phase II Efficacy, Activity and Safety Study of GLQ223 Alone and in Combination With Zidovudine in Symptomatic HIV-Infected Patients Without Prior Treatment With GLQ223 or Trichosanthin
This study involves GLQ223 administration to patients who have not previously been exposed to it, but who have received at least 9 months of zidovudine therapy.
- Trial name
- NCT00001989
- Testing
- Trichosanthin, Zidovudine
- Where
- 8 sites in United States
- Sponsor
- Genelabs Technologies
HIV Infections, Cardiovascular Diseases
Implementation and Effectiveness of Physical Activity to Prevent Disability in HIV-infected Adults Older Than 50 From Côte d'Ivoire
The overall objective of this research is to provide evidence on the effectiveness and implementation of two strategies deliver a structured programme of physical activity (PA) people living with HIV older than 50 years from…
- Conditions
- HIV Infections, Cardiovascular Diseases, Insulin Resistance Syndrome X
- Trial name
- VIRAGE+ (NCT06139497)
- Testing
- Physical activity programme, Home-based physical activity
- Where
- 2 sites in Côte d’Ivoire
- Volunteers
- 180 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections
Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or Didanosine
To evaluate the efficacy, safety, and pharmacokinetics of lamivudine (3TC) combined with zidovudine (AZT), stavudine (d4T), or didanosine (ddI) in comparison with d4T or ddI monotherapy in HIV-infected patients with no prior…
- Trial name
- NCT00000838
- Testing
- Lamivudine, Stavudine, Zidovudine
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 256 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)